When Pfizer ( PFE) serves up its second-quarter financial report on Thursday, it will truly mark a dividing line between the past and the future. The second quarter represents the last three months of sales for Lipitor before the cholesterol-fighter started competing with generic versions of Zocor, the Merck ( MRK) drug that lost U.S patent protection last month, and the final quarter of unfettered revenue for Pfizer's third-best seller Zoloft, the antidepressant whose patent has now expired. At the same time, the sun is setting on the days when Pfizer's nonprescription drugs and consumer products divisions will contribute to earnings. Pfizer has agreed to sell them to Johnson & Johnson ( JNJ) for $16.6 billion , and the sides expect to close the deal by the end of the year. On Monday, Pfizer said it would treat the consumer products unit as a discontinued operation, a move required by generally accepted accounting principles. While analysts will examine the second quarter's impact on the future, they also want to know specifically about upcoming products. Pfizer executives can expect questions on the marketing and pricing of Exubera, the inhaled insulin developed with Nektar Therapeutics ( NKTR) being launched this month, and they'll likely be pressed for details on the pricing and launch of Chantix , the antismoking drug approved by the Food and Drug Administration in May. Pfizer has said Chantix will be available during the second half of the year. The company will probably also be asked to discuss the cancelled partnership with Neurocrine Biosciences ( NBIX) for the troubled insomnia drug Indiplon , and for an update on torcetrapib, an experimental drug that raises so-called good cholesterol. Torcetrapib is one of the products that Pfizer hopes will mitigate the damage caused by prominent medications losing patent protection. Of course, Lipitor's sales growth will be the primary point for discussion. The U.S. performance of the world's bestselling drug "captures top billing on investors' minds as the key topic for the quarter," Chris Shibutani of JPMorgan wrote in a recent research report. He wonders if Pfizer can fulfill the promise made earlier this year by Hank McKinnell, the chairman and CEO, that Lipitor could achieve at least $13 billion in sales this year. Shibutani forecasts $12.3 billion, or about the same as last year's $12.2 billion.